Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Bought by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC increased its stake in Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) by 73.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 707 shares of the life sciences company’s stock after buying an additional 300 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Integra LifeSciences were worth $45,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of IART. Covestor Ltd acquired a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $64,000. UMB Bank N A MO purchased a new position in Integra LifeSciences in the fourth quarter valued at about $69,000. First Horizon Advisors Inc. boosted its holdings in Integra LifeSciences by 428.4% in the fourth quarter. First Horizon Advisors Inc. now owns 1,189 shares of the life sciences company’s stock valued at $79,000 after purchasing an additional 964 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in Integra LifeSciences in the fourth quarter valued at about $162,000. Finally, Versor Investments LP purchased a new position in Integra LifeSciences in the fourth quarter valued at about $221,000. Institutional investors and hedge funds own 93.32% of the company’s stock.

Integra LifeSciences Stock Down 0.5 %

Shares of Integra LifeSciences stock opened at $55.06 on Friday. The company has a current ratio of 3.85, a quick ratio of 2.76 and a debt-to-equity ratio of 0.90. The business’s 50 day simple moving average is $56.11 and its 200-day simple moving average is $61.13. The stock has a market capitalization of $4.60 billion, a price-to-earnings ratio of 27.95, a PEG ratio of 1.78 and a beta of 1.09. Integra LifeSciences Holdings Co. has a twelve month low of $51.21 and a twelve month high of $76.70.

Analyst Ratings Changes

IART has been the subject of a number of analyst reports. StockNews.com raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, April 30th. Citigroup reduced their price target on Integra LifeSciences from $70.00 to $67.00 and set a “neutral” rating for the company in a report on Tuesday, May 17th. Piper Sandler reduced their price target on Integra LifeSciences from $66.00 to $55.00 in a report on Wednesday, July 27th. Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, July 25th. They set an “equal weight” rating and a $59.00 target price on the stock. Finally, Truist Financial reduced their target price on Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating on the stock in a report on Wednesday, July 20th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus target price of $66.29.

Insider Transactions at Integra LifeSciences

In other news, EVP Lisa Evoli sold 900 shares of the stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $55.93, for a total transaction of $50,337.00. Following the sale, the executive vice president now directly owns 19,911 shares in the company, valued at approximately $1,113,622.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 1,587 shares of company stock worth $90,108. 4.20% of the stock is currently owned by company insiders.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Read More

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.